SCHEMBL7753239

SCHEMBL7753239

Nc1ccc(CNC(=O)CCl)cc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TPSAB1 Q15661 5/20 0.53
EPHX2 P34913 1/20 0.49
PPID Q08752 3/20 0.48
MAPK1 P28482 1/20 0.48
ALDH1A1 P00352 3/20 0.47
HTT P42858 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
EPHX1 P07099 1/20 0.47
CYP2C9 P11712 1/20 0.47
CYP2C19 P33261 1/20 0.47
PPIB P23284 1/20 0.46
PPIA P62937 1/20 0.46
PPIG Q13427 1/20 0.46
POLB P06746 1/20 0.46
MAPT P10636 1/20 0.46
RAB9A P51151 1/20 0.46
PRSS1 P07477 1/20 0.46
MEN1 O00255 1/20 0.46
KMT2A Q03164 1/20 0.46
CA1 P00915 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22852533 0.85 TPSAB1 (0.58) TPSAB1EPHX2PPIDALDH1A1HTT
SCHEMBL9798143 0.84 ALDH1A1 (0.58) TPSAB1EPHX2MAPK1ALDH1A1HTT
SCHEMBL6850677 0.83 ESRRG (0.53) PPIDALDH1A1CA1CA2LMNA
SCHEMBL21781874 0.82 CA1 (0.64) TPSAB1EPHX2PPIDEPHX1CYP2C9
SCHEMBL18868428 0.82 ALDH1A1 (0.61) TPSAB1ALDH1A1MAPTRAB9AMEN1
SCHEMBL4035227 0.82 KMT2A (0.68) ALDH1A1SMN1; SMN2CYP2C9CYP2C19POLB
SCHEMBL3517253 0.81 TPSAB1 (0.53) TPSAB1EPHX2PPIDHTTEPHX1
SCHEMBL22500066 0.81 L3MBTL1 (0.62) TPSAB1MAPK1ALDH1A1HTTSMN1; SMN2
SCHEMBL15651444 0.81 PPID (0.54) TPSAB1EPHX2PPIDALDH1A1EPHX1
SCHEMBL11731507 0.81 KMT2A (0.65) ALDH1A1SMN1; SMN2POLBRAB9AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7592356-B2 Triazoles as farnesyl transferase inhibitors JANSSEN PHARMACEUTICA N.V. (BE) 2009-09-22 US disclosed
US-20080103150-A1 Triazoles as Farnesyl Transferase Inhibitors SAHA ASHIS K 2008-05-01 US disclosed
EP-1068390-A1 METHOD FOR IMPROVED WET STRENGTH PAPER Kimberly-Clark Worldwide, Inc. (US) 2001-01-17 EP disclosed
WO-1999045201-A1 METHOD FOR IMPROVED WET STRENGTH PAPER KIMBERLY-CLARK WORLDWIDE, INC. (US) 1999-09-10 WO disclosed
US-5935383-A Method for improved wet strength paper KIMBERLY-CLARK WORLDWIDE, INC. (US) 1999-08-10 US disclosed
US-4141890-A FIBER-REACTIVE CIBA-GEIGY CORPORATION (US) 1979-02-27 US disclosed
US-4067864-A FOR CELLULOSE OR POLYAMIDES CIBA-GEIGY AG (CH) 1978-01-10 US disclosed
US-4039523-A YELLOW CIBA-GEIGY AG (CH) 1977-08-02 US disclosed
US-4017477-A 3-Halogeno-6-hydroxy-pyridone-(2) azo dyestuffs CIBA-GEIGY AG (CH) 1977-04-12 US disclosed
US-4001203-A Heavy metal complexes of azo dyestuffs containing a heterocyclic diazo component and the residue of 5-halogeno-2,3-dihydrozypyridine as coupling component CIBA-GEIGY AG (CH) 1977-01-04 US disclosed
US-3971738-A Heavy metal complexes of azo compounds containing a halogeno-2,3-dihydroxy pyridine coupling component CIBA-GEIGY AG (CH) 1976-07-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080103150-A1 Triazoles as Farnesyl Transferase Inhibitors CYP7A1, HSD3B1, CES1 TPSAB1 423/4885EPHX2 352/4885PPID 4392/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.